Federated Hermes
CTIC

Federated Hermes’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Federated Hermes’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1
Closed -$1K – 2347
2022
Q3 		$1K Sell
1
-187
-99% -$1.17K ﹤0.01% 2131
2022
Q2 		$1K Buy
+188
New +$963 ﹤0.01% 2126
2020
Q3 		– Sell
-209
Closed -$1K – 2424
2020
Q2 		$1K Sell
209
-458
-69% -$484 ﹤0.01% 2223
2020
Q1 		$1K Hold
667
– – ﹤0.01% 2223
2019
Q4 		$1K Hold
667
– – ﹤0.01% 2196
2019
Q3 		$1K Sell
667
-1,344
-67% -$1.03K ﹤0.01% 2187
2019
Q2 		$2K Hold
2,011
– – ﹤0.01% 2094
2019
Q1 		$2K Hold
2,011
– – ﹤0.01% 2089
2018
Q4 		$1K Hold
2,011
– – ﹤0.01% 2179
2018
Q3 		$4K Sell
2,011
-436
-18% -$1.08K ﹤0.01% 2102
2018
Q2 		$12K Buy
2,447
+1,183
+94% +$5.18K ﹤0.01% 1888
2018
Q1 		$5K Buy
+1,264
New +$4.45K ﹤0.01% 1983

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Federated Hermes's CTIC Position: Q4 2022 in Review

Federated Hermes sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2022, closing a stake of 1 share — an estimated $1K sold.

Federated Hermes first reported a position in CTIC in Q1 2018 and held it in 12 quarters. The position peaked at $12K in Q2 2018. 145 funds tracked by Wall St. Rank hold CTIC as of Q4 2022.

  • Federated Hermes reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2022 after selling out during the quarter.
  • Federated Hermes sold 1 CTI BioPharma Corp. (DE) Common Stock share in Q4 2022, an estimated $1K.
  • Federated Hermes first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2018 and held it in 12 quarters.
  • Federated Hermes's CTI BioPharma Corp. (DE) Common Stock position peaked at $12K in Q2 2018.
  • 145 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2022.

Based on Federated Hermes's 13F filing for Q4 2022, filed 13 Feb 2023.